SCHEMBL17016142

SCHEMBL17016142

c1ccc(-n2c3ccccc3c3ccc4c(ccn4-c4cccc(-c5ccc6cc7ccccc7cc6c5)c4)c32)cc1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 2/20 0.37
KDM4E B2RXH2 1/20 0.37
ATM Q13315 1/20 0.37
WNK1 Q9H4A3 2/20 0.34
HSD17B1 P14061 4/20 0.33
HSD17B2 P37059 4/20 0.33
OPRD1 P41143 1/20 0.32
KMT2A Q03164 2/20 0.31
CYP1A2 P05177 1/20 0.31
CYP3A4 P08684 1/20 0.31
CYP2D6 P10635 1/20 0.31
CYP2C9 P11712 1/20 0.31
CYP2B6 P20813 1/20 0.31
CYP2C19 P33261 1/20 0.31
IL1R1 P14778 1/20 0.31
MEN1 O00255 1/20 0.30
ALDH1A1 P00352 1/20 0.30
MAPT P10636 1/20 0.30
HTT P42858 1/20 0.30
RXFP1 Q9HBX9 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17015194 0.96 KDM4E (0.34) L3MBTL1KDM4EATMWNK1HSD17B1
SCHEMBL17015658 0.94 WNK1 (0.33) L3MBTL1KDM4EATMWNK1HSD17B1
SCHEMBL17016130 0.93 KDM4E (0.37) L3MBTL1KDM4EATMWNK1HSD17B1
SCHEMBL17015740 0.93 WNK1 (0.32) L3MBTL1KDM4EATMWNK1HSD17B1
SCHEMBL17016140 0.92 KDM4E (0.38) L3MBTL1KDM4EATMTUBB4ATUBB
SCHEMBL17015657 0.92 KDM4E (0.35) L3MBTL1KDM4EATMHSD17B1HSD17B2
SCHEMBL17015193 0.92 KDM4E (0.38) L3MBTL1KDM4EATMTUBB4ATUBB
SCHEMBL17015739 0.91 NR3C1 (0.33) L3MBTL1KDM4EATM
SCHEMBL17016141 0.90 KDM4E (0.41) L3MBTL1KDM4EATMALDH1A1MAPK9
SCHEMBL15631999 0.90 L3MBTL1 (0.41) L3MBTL1KDM4EATMWNK1OPRD1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9837618-B2 Compound and organic electroluminescence device including thesame DOOSAN CORPORATION (KR) 2017-12-05 US disclosed
US-9837618-B2 Compound and organic electroluminescence device including thesame DOOSAN CORPORATION (KR) 2017-12-05 US disclosed
US-20150236272-A1 NOVEL COMPOUND AND ORGANIC ELECTROLUMINESCENCE DEVICE INCLUDING THESAME DOOSAN CORPORATION (KR) 2015-08-20 US disclosed
US-20150236272-A1 NOVEL COMPOUND AND ORGANIC ELECTROLUMINESCENCE DEVICE INCLUDING THESAME DOOSAN CORPORATION (KR) 2015-08-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150236272-A1 NOVEL COMPOUND AND ORGANIC ELECTROLUMINESCENCE DEVICE INCLUDING THESAME INMT, IDO1, IDO2 L3MBTL1 533/4885KDM4E 1286/4885ATM 3623/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.